The value of biotechs could more than double: Kinea highlights how beneficial the union of medicine and AI is for the sector

A.I Emphasis Innovation

A montage using laboratory elements, a Petri dish, and a DNA helix to illustrate the theme of biotechnology. Image generated by AI.

Kinea published a report on Thursday morning (12) about the use of artificial intelligence (AI) in the field of medical technology companies, called biotechs .

“Artificial intelligence is already accelerating drug discovery, but the decisive test is in the clinical phases and depends on biological data,” the report begins.

This is because the current situation presents an opportunity that combines biotechs at attractive prices with those who supply equipment, tools, and clinical trials — companies that tend to profit even when more molecules tested do not necessarily mean more approvals.

Going back a bit, there are several stages before a company launches a drug on the market. The so-called phase 2 is considered the “valley of death” for these drugs: it’s when clinical trials begin and the effectiveness of the new drug is assessed.

According to Kinea analysts, AI has already deciphered the shape of proteins, designs molecules in months, and has demonstrated success in phase 1. However, there has been no verdict yet on phases 2 and 3.

“In a biotech company in the clinical trial phase, the value depends on the likelihood of its drugs reaching the market: if that probability of success rises from 8% to 12%, the value increases by about 50%. If it reaches 18%, it more than doubles,” the analysts write.

Biotechs are leading the sector, according to Kinea.

Among the companies most cited as leaders in the new frontier of biotechnology with AI, Kinea highlights Insilico Medicine , developer of the experimental drug Rentosertib for idiopathic pulmonary fibrosis — a disease that scars the walls of the lungs.

The case is presented as one of the most advanced examples of drug discovery guided by artificial intelligence. The company managed to identify a therapeutic target and develop a candidate molecule in about 18 months, compared to a traditional timeframe of 4 to 5 years.

“Rentosertib has already advanced to phase 3 of clinical trials, which could represent a milestone for the industry if it obtains regulatory approval,” the study says.

Another company mentioned is Recursion, which operates in the field of “cellular phenomics,” using large biological databases and AI to accelerate drug discovery. The company is cited as an example of the application of artificial intelligence in the laboratory stage, especially in cell analysis and the generation of biological data.

Shovels and pickaxes in the biotech field.

Despite this, Kinea’s conclusion is that the best risk-return ratio today may not lie with individual biotech companies, but with the so-called “shovel and pickaxe suppliers” in the AI ​​race in healthcare.

Among the prominent names are IQVIA (one of the main beneficiaries if AI increases the number of molecules entering clinical trials, as it is a third-party clinical research and clinical trial services company), ICON (provides services for the design, execution, and monitoring of clinical studies), Thermo Fisher Scientific (suppliers of equipment and reagents for laboratories), Danaher (provides instruments, laboratory equipment, diagnostic tools, and other technologies for research), and 10x Genomics (supplier of technologies for cell analysis).

Thus, the management company shows a greater preference for companies linked to equipment, tools, and clinical trials, which tend to benefit even in scenarios where AI accelerates the discovery of molecules without necessarily increasing the drug approval rate.

Source: www.moneytimes.com.br
Source link

Leave a Reply

Your email address will not be published. Required fields are marked *

16 − 5 =